Share this article LAS VEGAS, March 11, 2021 /PRNewswire/ -- DelveInsight's " Treatment-Resistant Depression (TRD) Market" report provides a thorough comprehension of the Treatment-Resistant Depression, historical and forecasted epidemiology, and the TRD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. Some of the vital points of the The FDA approved SYMBYAX for acute treatment of TRD and depressive episodes associated with Bipolar Disorder in adults in March 2009. In March 2019, the FDA approved